A Phase 2 interventional study of NMDA and Sertraline in Depressive Disorder, Major, sponsored by Chang Gung Memorial Hospital. Completed at 2 sites in Taiwan. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2020-12-01.
Sponsored by Chang Gung Memorial Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Depressive Disorder, Major with a site in Taiwan — 13 open to participants now, 13 under way, 6 of them phase 3. Depressive Disorder, Major · Taiwan.
Among the 69 studies in Depressive Disorder, Major with a site in Taiwan, this one is the 32nd largest by enrollment of the 64 interventional ones that give a count, is one of 4 that started in 2016, is one of 8 in phase 2, and was the 34th registered.
3,050 studies on the registry are indexed under Depressive Disorder, Major; 594 are open to participants now.
Browse Depressive Disorder, Major studies →13 of the 69 studies in Depressive Disorder, Major with a site in Taiwan are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Taiwan, United States, Australia and 12 more countries
Ages 18–75
Janssen Research & Development, LLC · Sites in Taiwan, United States, Argentina and 4 more countries
Ages 18–74
Eli Lilly and Company · Sites in Taiwan, United States, Australia and 12 more countries
Ages 18–75
Janssen Research & Development, LLC · Sites in Taiwan, United States, Brazil and 4 more countries
Ages 12–17
National Science and Technology Council, Taiwan · Sites in Taiwan
Ages 50–80
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 417 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 297 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 19 · Phase 4 10
First in 2005; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 136 is above the median of 79 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 128 across the 64 interventional studies, 160 across the 5 observational. Of the 43 that completed or were terminated, 17 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 69 have an industry lead sponsor. The 10 most frequent:
Chang Gung Memorial Hospital is the lead sponsor of 1,098 studies on the registry; 241 are open to participants now.
Chang Gung Memorial Hospital has 4 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
4 of the studies in Depressive Disorder, Major with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04637620China Medical University HospitalNMDA Modulation in Major Depressive Disorder | 2026-11 |
| NCT05136755China Medical University HospitalNMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder | 2026-11 |
| NCT06821646National Taiwan University HospitalInvestigating the Brain's Physiological Responses in Depression and Autism, Using Transcranial Magnetic Stimulation and Electroencephalography | 2026-12-31 |
| NCT07500714National Science and Technology Council, TaiwanIntegrating Digital Phenotypes and AI-Driven Cognitive-Behavioral Therapy: Advancing Precision Medicine in Depression Through Digital Medicine | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 69 studies in Depressive Disorder, Major with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Major depressive disorder (MDD) is a complex and multi-factorial disorder. Most of the current antidepressants are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. Many elderly patients have significant side effects after treatment with antidepressants which hamper the motivation for treatment and medication adherence. NMDA hypofunction has been implicated in the pathophysiology of depression. MDD in the elderly is often associated with cognitive deficits which are not necessarily recovered by current antidepressants. The NMDA receptor regulates synaptic plasticity, memory, and cognition. In our previous studies, cognitive improvement has been observed with treatment of NMDA enhancers. Therefore, this study will examine the efficacy and safety as well as cognitive function improvement of NMDAE in the treatment of MDD in the elderly by comparing with sertraline (a selective serotonin reuptake inhibitor [SSRI]) and placebo.
The investigator will enroll elderly patients with MDD for an 8-week treatment. All patients will be randomly assigned into three groups: NMDAE, sertraline, or placebo. The investigator will biweekly measure clinical performances. Cognitive functions will be assessed at baseline and at endpoint of treatment by a battery of tests. The investigator hypothesize that NMDAE can safely yield better efficacy than placebo and sertraline for elderly patients with MDD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An NMDA enhancer
Drug: NMDA
Sertraline
Drug: Sertraline
Placebo
Drug: Placebo - Cap
Use of an NMDA enhancer for the treatment of MDD in late life
Also known as: NMDAE
Use of SSRI as an active comparator
Use of placebo as a comparator
Change from baseline of 17-item Hamilton Rating Scale for Depression
Assessment of depressive symptoms. The 17-item Hamilton Rating Scale for Depression will be measured biweekly.
Time frame: Week 0, 2, 4, 6, 8
Change from baseline of Perceived Stress Scale
Assessment of stress and anxiety symptoms. The Perceived Stress Scale will be measured biweekly
Time frame: Week 0, 2, 4, 6, 8
Drop out rate
The rate of drop out
Time frame: Week 0, 2, 4, 6, 8
Change from baseline of Geriatric Depression Scale
Assessment of geriatric depressive symptoms. The Geriatric Depression Scale will be measured biweekly
Time frame: Week 0, 2, 4, 6, 8
Clinical Global Impression
Assessment of global improvement
Time frame: Week 2, 4, 6, 8
Cognitive function
A battery of tests to assess the cognitive function including speed of processing (category fluency) and verbal and nonverbal working memory
Time frame: Week 0, 8
Change from baseline of Beck's Suicide Scale
Assessment of suicidal symptoms. The Beck's Suicide Scale will be measured biweekly
Time frame: Week 0, 2, 4, 6, 8
Ran from Jan 2016 to primary completion in Nov 2020, 58 months.
Of 99 non-industry phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 57. This study's 58 months is above that.
Counting every sponsor, half of 197 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chang Gung Memorial Hospital →